Current-law scope and cautions
- China GCP requires prompt SAE communication and sponsor pharmacovigilance handling, but a universal “all SAE to NMPA within 24 hours” rule should not be used.
- Expedited regulatory reporting depends on the event classification (including SUSAR) and applicable drug-safety rules/protocol.
- Data authenticity, traceability, informed consent, monitoring, vendor oversight and essential-document retention are core inspection themes.
Use: This is a screening/estimation tool, not a legal opinion. Confirm the latest primary authority, regulator practice, local rules and transaction documents before acting.
